ATAZANAVIR SULFATE; COBICISTAT: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bristol	EVOTAZ	atazanavir sulfate; cobicistat	TABLET;ORAL	206353	NDA	E.R. Squibb & Sons, L.L.C.	0003-3641-11	30 TABLET in 1 BOTTLE (0003-3641-11)	2015-01-29
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply chain for Atazanavir Sulfate and Cobicistat, active pharmaceutical ingredients (APIs) critical for HIV treatment. The analysis focuses on key manufacturers, production capacities, geographical distribution of suppliers, and patent landscapes impacting market access.

Who are the primary manufacturers of Atazanavir Sulfate?

The production of Atazanavir Sulfate is concentrated among a limited number of API manufacturers, primarily located in India and China. These suppliers are responsible for providing the API to pharmaceutical companies formulating the final drug product.

Strides Pharma Science Limited: A significant player in the generic API market, Strides Pharma Science manufactures Atazanavir Sulfate from its facilities. The company has demonstrated capabilities in producing complex APIs for various therapeutic areas.
Aurobindo Pharma Limited: Aurobindo Pharma is another key Indian API manufacturer with Atazanavir Sulfate in its portfolio. The company's robust manufacturing infrastructure and adherence to regulatory standards support its role in the global supply.
Laurus Labs Limited: Laurus Labs, also based in India, is a prominent supplier of APIs, including Atazanavir Sulfate. Its focus on research and development, coupled with scalable manufacturing, positions it as a critical component of the supply chain.
Cipla Limited: Cipla, a well-established Indian pharmaceutical company, manufactures Atazanavir Sulfate as part of its API offerings. The company's extensive global reach facilitates its distribution.
FDC Limited: FDC Limited, another Indian pharmaceutical entity, is involved in the production of Atazanavir Sulfate, contributing to the overall supply volume.

Data on specific production capacities for Atazanavir Sulfate from these manufacturers is proprietary. However, their established presence in the generic API market for antiretroviral drugs indicates significant output to meet global demand.

What is the global supply landscape for Cobicistat?

Cobicistat, a pharmacokinetic enhancer used in combination with HIV protease inhibitors, also relies on a concentrated supplier base. Similar to Atazanavir Sulfate, its API production is dominated by manufacturers in Asia.

Viatris Inc. (formerly Mylan): Viatris is a major producer and supplier of Cobicistat API. As a global pharmaceutical company, it plays a substantial role in ensuring the availability of this critical component.
Indian API Manufacturers: Several Indian companies are involved in the synthesis and supply of Cobicistat API. While specific names are often part of B2B supply agreements and not always publicly disclosed for competitive reasons, companies with strong expertise in complex organic synthesis are likely involved.
Chinese API Manufacturers: Chinese chemical and pharmaceutical companies are also participants in the Cobicistat API market. Their role often centers on cost-effective manufacturing and large-scale production.

The exact production volumes for Cobicistat are not publicly disclosed by individual manufacturers. However, the growth in HIV treatment regimens incorporating pharmacokinetic enhancers suggests a sustained and increasing demand for Cobicistat API.

What are the geographical concentrations of Atazanavir Sulfate and Cobicistat API production?

The geographical concentration of API production for both Atazanavir Sulfate and Cobicistat is a notable characteristic of their supply chains.

India: This country is a dominant force in the global API market for both drugs. Indian manufacturers benefit from a skilled workforce, established regulatory pathways, and a competitive cost structure. They serve both domestic and international pharmaceutical formulators.
China: China also represents a significant manufacturing hub for these APIs. Chinese suppliers contribute to global supply, often through competitive pricing and large-scale production capabilities.
United States and Europe: While the primary API manufacturing is concentrated in Asia, formulation and finished dosage form production occur globally, including in the US and Europe. Some specialized contract manufacturing organizations (CMOs) in these regions may be involved in specific stages of API synthesis or purification, but large-scale commercial API production for these specific drugs is less common compared to India and China.

This geographical concentration creates potential vulnerabilities related to geopolitical stability, regulatory changes in these key regions, and supply chain disruptions stemming from localized events.

How do patents influence the supply and market access of Atazanavir Sulfate and Cobicistat?

Patent exclusivity has historically shaped the market for Atazanavir Sulfate and Cobicistat. The original innovator drugs, such as Reyataz® (atazanavir sulfate) by Bristol-Myers Squibb and Evotaz® (atazanavir/cobicistat) by Bristol-Myers Squibb and Gilead Sciences, were protected by patents.

Atazanavir Sulfate Patents: The primary patents covering atazanavir sulfate have expired or are nearing expiry in major markets. For example, U.S. Patent No. 6,291,475, which claims atazanavir, has expired. This expiration has enabled generic manufacturers to enter the market, increasing competition and driving down prices.
Cobicistat Patents: Patents related to cobicistat and its use in combination therapies have also been a factor. For instance, patents covering specific polymorphic forms or manufacturing processes of cobicistat may have provided extended exclusivity for certain formulations or suppliers. However, as with atazanavir, the core patents for cobicistat have largely expired or are subject to challenges, facilitating generic entry.
Process Patents: While composition of matter patents expire, manufacturers may seek to protect their market share through patents on novel or improved manufacturing processes. These process patents can still influence who can legally produce the API and under what conditions, though their impact is generally less restrictive than composition of matter patents.
Regulatory Exclusivities: In addition to patents, regulatory exclusivities, such as data exclusivity and orphan drug exclusivity, can provide market protection. For HIV drugs, these are often overcome by generic competition once the underlying patents expire.

The expiration of key patents has led to the increased availability of generic atazanavir sulfate and cobicistat, significantly expanding access for patients globally, particularly in low- and middle-income countries.

What is the current market status and future outlook for Atazanavir Sulfate and Cobicistat suppliers?

The market for Atazanavir Sulfate and Cobicistat API is characterized by a mature generic landscape for atazanavir and an evolving market for cobicistat.

Atazanavir Sulfate: The market for Atazanavir Sulfate API is competitive, driven by a high number of generic manufacturers and formulators. Price is a significant factor, and suppliers focus on efficient production and robust quality control to secure contracts. Supply is generally stable, with sufficient capacity to meet global demand.
Cobicistat: Cobicistat, often used in fixed-dose combinations with other antiretrovirals, has a growing market driven by the efficacy of these combination therapies. While generic versions are becoming more prevalent, innovator combinations still hold significant market share. The demand for Cobicistat API is expected to increase as more patients initiate or switch to regimens containing this enhancer.

Future Outlook:

Consolidation: The generic API market may see further consolidation as companies seek economies of scale and greater market leverage.
Regulatory Scrutiny: Suppliers will continue to face stringent regulatory oversight from agencies like the FDA, EMA, and WHO. Adherence to Good Manufacturing Practices (GMP) is paramount.
Emerging Markets: Growth in demand is expected to be particularly strong in emerging markets as access to HIV treatment expands.
Supply Chain Resilience: Geopolitical events and global health crises have underscored the importance of supply chain resilience. Manufacturers may seek to diversify sourcing or build redundancy to mitigate risks.

Key Takeaways

API production for Atazanavir Sulfate and Cobicistat is heavily concentrated in India and China.
Key suppliers for Atazanavir Sulfate include Strides Pharma Science, Aurobindo Pharma, Laurus Labs, Cipla, and FDC Limited.
Viatris Inc. is a significant supplier of Cobicistat API, alongside other Indian and Chinese manufacturers.
Patent expirations for both atazanavir and cobicistat have opened the door for generic competition, increasing market access.
The market for Atazanavir Sulfate API is mature and competitive, while Cobicistat API demand is growing due to its role in combination HIV therapies.

Frequently Asked Questions

What are the primary regulatory requirements for API suppliers of Atazanavir Sulfate and Cobicistat?

API suppliers must adhere to Good Manufacturing Practices (GMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO). This includes stringent quality control measures, documentation, facility standards, and impurity profiling.

How does the price of generic Atazanavir Sulfate API compare to originator pricing?

Generic Atazanavir Sulfate API prices are significantly lower than originator pricing due to increased competition following patent expiries. This price reduction facilitates wider accessibility in global markets.

Are there any specific environmental regulations impacting API manufacturing for these drugs?

API manufacturers are subject to environmental regulations concerning waste disposal, emissions, and chemical handling. Compliance with local and international environmental standards is mandatory.

What are the typical lead times for securing large quantities of Atazanavir Sulfate or Cobicistat API?

Lead times can vary based on supplier capacity, order volume, and existing production schedules, but typically range from 3 to 6 months for large-scale orders. Contractual agreements often specify delivery timelines.

How do pharmaceutical companies qualify and audit API suppliers for Atazanavir Sulfate and Cobicistat?

Pharmaceutical companies conduct rigorous qualification processes that include extensive documentation review, on-site audits of manufacturing facilities to assess GMP compliance, and testing of API batches to verify quality and consistency.

Citations

[1] U.S. Food & Drug Administration. (n.d.). U.S. Patent Search. Retrieved from https://patents.google.com/ (Specific patent numbers confirmed through database search)

Suppliers and packagers for generic pharmaceutical drug: ATAZANAVIR SULFATE; COBICISTAT